Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476112 · ClinicalTrials.gov registry record · Phase 2
A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
A Phase 2 study of Atrial Flutter, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00476112: Completed Phase 2 study of Atrial Flutter, sponsored by Advanz Pharma.
NCT00476112 is a Phase 2 study of Atrial Flutter that has completed, run by Advanz Pharma. The registered enrollment target is 60 participants, below the 2,121-participant average among 23 other Atrial Flutter trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00476112, a Phase 2 study of Atrial Flutter, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
Conditions Studied
Interventions
- DRUG Vernakalant Injection 20 mg/mL
Study Locations (20)
Other
- Aalborg University - Aalborg
- H:S Bispebjerg Hospital - Copenhagen
- Centralsygehuset Esbjerg Varde - Esbjerg
- Glostrup Amtssygehus - Glostrup Municipality
- Gentofte Amtssygehus - Hellerup
- Herlev Amtssygehus, Kardiologisk - Herlev
- Sygehus Vendsyssel Hjorring - Hjørring
Alberta
- Heart Health Institute, Rockyview General Hospital - Calgary
- University of Calgary - Calgary
- University of Alberta Hospital - Edmonton
Quebec
- Institut de Cardiologie de Montreal - Montreal
- Hopital Notre-Dame du CHUM - Montreal
- CHUM-Hotel-Dieu de Montreal - Montreal
Virginia
- Medical College of Virginia - Richmond
- McGuire VA Medical Center - Richmond
Ontario
- Hamilton Health Sciences, Hamilton General Hospital - Hamilton
- Ottawa Hospitals (Civic & General) - Ottawa
California
- Regional Cardiology Associates - Sacramento
Michigan
- Thoracic and Cardiovascular Institute - Lansing
Wisconsin
- Marshfield Clinic - Marshfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00476112 record still lists
NCT00476112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,121-participant average among 23 other Atrial Flutter trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atrial Flutter appearing as the primary indexed condition, and to 1 intervention - of which Vernakalant Injection 20 mg/mL is the first listed.
NCT00476112 names 20 study sites across 8 states, led by Other, Alberta, Quebec.
Frequently Asked Questions
What is clinical trial NCT00476112 about?
NCT00476112 is a clinical study titled "A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter". This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
What is the current status of trial NCT00476112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-08. Estimated completion is 2004-09.
What conditions does trial NCT00476112 study?
This clinical trial studies the following conditions: Atrial Flutter.
What interventions are being tested in trial NCT00476112?
The interventions under investigation include: Vernakalant Injection 20 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00476112?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00476112 being conducted?
This trial has 20 study locations across California, Michigan, Virginia, Wisconsin, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Flutter
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00476112's enrollment target sits among peer trials
60 19th of 23 higher than 5 of 23 other Atrial Flutter trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Flutter trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
COMPLETED · Phase 2
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
Get With the Guidelines Atrial Fibrillation Registry
RECRUITING
-
The Z Stitch Early Bed Rest Assessment Study
RECRUITING · NA
-
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
RECRUITING
-
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia